您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 法国药房
产地国家: 法国
所属类别: 抗癌药物->升血小板药物
处方药:处方药
包装规格: 250微克/0.5毫升/瓶
计价单位:
  点击放大  
生产厂家中文参考译名:
安进公司
生产厂家英文名:
Amgen
该药品相关信息网址1:
http://www.nplate.com/
该药品相关信息网址2:
http://www.drugs.com/nplate.html
该药品相关信息网址3:
http://www.rxlist.com/nplate-drug.htm
原产地英文商品名:
NPLATE 250MCG/0.5ML/vial
原产地英文药品名:
ROMIPLOSTIM
中文参考商品译名:
NPLATE 250微克/0.5毫升/瓶
中文参考药品译名:
罗米司亭
原产地国家批准上市年份:
2008/08/22
英文适应病症1:
Thrombopoietin drug
临床试验期:
完成
中文适应病症参考翻译1:
血小板生成药物
药品信息:

友情提示:该款药品需要从法国邮寄至英国再到美国,因此运费比较贵!

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201021920423214.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

美国FDA批准Nplate(romiplostim)作为首个并且是唯一的血小板生成药物,用于治疗脾切除及非脾切除的成人免疫性血小板减少症。Nplate为首个FDA批准的肽体蛋白,通过升高与维持血小板数而发挥作用,是长期治疗该慢性疾病的新方法。

慢性ITP是1种严重的自身免疫性疾病,其特征为血液中血小板计数低(血小板减少症),可能导致严重出血。

  本品的批准是基于2项双盲临床研究,纳入患者约125例,这些患者先前至少接受过1次ITP治疗。其中1项研究纳入的患者未进行脾切除,另1项中的患者则无脾。在为期6个月的研究中,接受本品治疗的患者,其血小板计数明显增高,并能维持。未进行脾切除的患者对本品的反应要高于脾切患者。

  在临床研究中,与本品相关的严重不良反应有骨髓网硬蛋白沉积、停用后血小板减少症恶化。其他用药风险包括由于血小板过度升高而引起血凝块。另外,如果患者骨髓发育不良而服用本品,可能引起急性白血病。针对本品的治疗风险,已开展“风险评估和减缓策略”(REMS)。

安进公司(Amgen)用于治疗罕见血凝异常疾病的药物——血小板生成素拟肽romiplostim(Nplate)已在欧洲通过批准,这使得该公司抢得先机,比GSK/ Ligand两家公司的同类药品Promacta更早进入欧洲市场。

   欧盟委员会批准Nplate用于治疗那些对目前常用药无应答的免疫性血小板减少性紫癜(ITP),但它仅获准作为二线药物用于那些未进行脾脏切除,且不适宜接受手术治疗的成人ITP患者。

   这次Nplate在欧洲获准基于2项III期临床研究。研究结果证实进行过或未进行过脾脏切除手术的患者用药治疗之后,他们体内的血小板读数均升高83%,并且保持稳定。有医务人员表示,Nplate是第一种在欧洲获准特别针对提高患者体内血小板数量,并且能长期使用的ITP治疗药。

   虽然患有ITP的人数量不多,据估计在欧洲有5万例慢性ITP患者,但这种病症会极大地影响他们的生活,而Nplate可以为他们带来福音。 

 安进公司负责人表示,此次Nplate在欧洲获准是该公司15年来辛勤努力的结果,同时作为第一种获准的肽体类药,其在该公司生物制剂的开发上也具有里程碑意义。2008年8月,本品已在美国获准。

-------------------------------------------------------------------

Important Safety Information

What is the most important information I should know about Nplate®?

Nplate® can cause uncommon but serious side effects:

Bone marrow changes (increased reticulin and possible bone marrow fibrosis). Long-term use of Nplate® may cause changes in your bone marrow. These changes may lead to abnormal blood cells or your body making less blood cells. The mild form of these bone marrow changes is called "increased reticulin." It is not known if this may progress to a more severe form called "fibrosis." The mild form may cause no problems while the severe form may cause life-threatening blood problems. Signs of bone marrow changes may show up as abnormalities in your blood tests. Your healthcare provider will decide if abnormal blood tests mean that you should have bone marrow tests or if you should stop taking Nplate®.

Worsening low blood platelet count (thrombocytopenia) and risk of bleeding shortly after stopping Nplate®. When you stop receiving Nplate®, your low blood platelet count (thrombocytopenia) may become worse than before you started receiving Nplate®. These effects are most likely to happen shortly after stopping Nplate® and may last about 2 weeks. The lower platelet counts during this time period may increase your risk of bleeding, especially if you are taking a blood thinner or other medicine that affects platelets. Your healthcare provider will check your blood platelet counts for at least two weeks after you stop taking Nplate®. Call your healthcare provider right away to report any bruising or bleeding.

High platelet counts and higher chance for blood clots. You have a higher chance of getting a blood clot if your platelet count is too high during treatment with Nplate®. You may have severe complications or die from some forms of blood clots, such as clots that spread to the lungs or that cause heart attacks or strokes. Your healthcare provider will check your blood platelet counts and change your dose or stop Nplate® if your platelet counts get too high.

Worsening of blood cancers. Nplate® is not for use in patients with blood cancer or a precancerous condition called myelodysplastic syndrome (MDS). If you have one of these conditions, Nplate® may worsen your cancer or condition and may cause you to die sooner.

Lack or loss of response: If you do not experience results from Nplate® your body may have created cells that are counteractive to Nplate®. Your healthcare provider will monitor your platelet counts and test your blood regularly to determine if this is an issue. Your healthcare provider will check your platelet count every week and change your dose of Nplate® as needed. This will continue until your healthcare provider decides that your dose of Nplate® can stay the same. After that, you will need to have blood tests every month. When you stop receiving Nplate®, you will need blood tests for at least 2 weeks to check if your platelet count drops too low.

Nplate® is only:
Prescribed by healthcare providers who are enrolled in the Nplate® NEXUS Program.
Given to patients who are enrolled in the Nplate® NEXUS Program.
Given by the enrolled healthcare provider or a provider under their direction. You may not give Nplate® injections to yourself.
Nplate® is for treatment of certain people with low blood platelet counts caused by chronic ITP, not low platelet counts caused by other conditions or diseases.

What are the possible side effects of Nplate®?
Nplate® may cause serious side effects. See "What is the most important information I should know about Nplate®?"

The most common side effects of Nplate® are:

  • Headache
  • Joint pain
  • Dizziness
  • Trouble sleeping
  • Muscle tenderness or weakness
  • Pain in arms and legs
  • Abdominal pain
  • Shoulder pain
  • Indigestion
  • Tingling or numbness in hands and feet

These are not all the possible side effects of Nplate®. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201021920423214.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2014-1-15
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com